CorMedix Inc. reported the first quarter ended March 31, 2026 results: revenue $127.4 million, net income $38.6 million, EPS $0.48 and $0.43 per share. Guidance raised.
“reference in such a filing. --- EX-99.1 (EX-99.1) --- CORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today”
Earnings Releases
CorMedix Inc. updated its the fourth quarter and full year ended December 31, 2025 guidance (reaffirmed).
“On March 5, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.”
M&A Transactions
CorMedix Inc. underwent a change of control involving Melinta Therapeutics, LLC for $260 million in cash and $40 million worth of common shares (closed 2025-08-29).
“at the effective time of the Merger (the “Effective Time”), the Company (i) paid to the Melinta equityholders (including the Consenting Melinta Members) an aggregate of $260 million in cash (subject to adjustment for the Aggregate Exercise Price, Estimated Company Cash, Estimated Company Debt, Estimated Working Capital as compared to the Working Capital”
Auditor Changes
CorMedix Inc. engaged CBIZ CPAs P.C. as its auditor.
“CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”
Auditor Changes
Marcum LLP resigned as auditor of CorMedix Inc..
“Marcum resigned as the Company’s independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”
Earnings Releases
CorMedix Inc. reported first quarter ended March 31, 2024 results: net income net loss of $14.5 million, EPS $0.25 per share.
“CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024”
Earnings Releases
CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.
“For the fourth quarter of 2023, CorMedix recorded a net loss of $14.8 million, or $0.26 per share”
Phoebe Mounts departed as Executive Vice President, General Counsel and Corporate Secretary at CorMedix Inc..
“On December 12, 2023, upon mutual agreement between CorMedix Inc. (the “Company”) and Phoebe Mounts, Ph.D., Esq., the Company’s Executive Vice President, General Counsel and Corporate Secretary, the Board of Directors of the Company (the “Board”) approved the separation of employment of Dr. Mounts, effective December 31, 2023”
Earnings Releases
CorMedix Inc. reported nine months ended September 30, 2023 results: net income net loss of $31.6 million, or $0.65 per share, EPS $0.65 per share.
“For the nine months ended September 30, 2023, CorMedix recorded a net loss of $31.6 million, or $0.65 per share, compared with a net loss of $21.5 million, or $0.54 per share, in the first nine months of 2022.”
Earnings Releases
CorMedix Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.7 million, or $0.17 per share, EPS $0.17 per share.
“For the third quarter of 2023, CorMedix recorded a net loss of $9.7 million, or $0.17 per share, compared with a net loss of $6.9 million, or $0.17 per share, in the third quarter of 2022.”
Shareholder Votes
CorMedix Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-10-26 meeting.
“Proposal No. 3 - Ratification of Appointment of Independent Registered Public Accounting Firm . Proposal No. 3 was to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal was approved. The results of the vote taken were as follows: FOR AGAINST ABSTAIN 37,796,427 700,384 255,165”
Shareholder Votes
CorMedix Inc. shareholders approved Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers for 2022 at the 2023-10-26 meeting.
“Proposal No. 2 – Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers for 2022 . Proposal No. 2 was to approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers for 2022, as disclosed in the Proxy Statement. The proposal was approved. The results of the vote taken were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 12,781,884 4,234,480 123,537 21,612,075”
Shareholder Votes
CorMedix Inc. shareholders approved Election of Directors at the 2023-10-26 meeting.
“The following individuals, each of whom was named as a nominee in the Proxy Statement, were elected by the Company’s stockholders by a plurality of votes cast to serve on the Company’s board of directors until the Company’s 2024 annual meeting of stockholders. Information on the vote relating to each director standing for election is set forth below: Nominee FOR WITHHELD BROKER NON-VOTES Janet Dillione 10,598,504 6,541,397 21,612,075 Gregory Duncan 15,929,357 1,210,544 21,612,075 Alan W. Dunton 15,731,113 1,408,788 21,612,075 Myron Kaplan 11,246,141 5,893,760 21,612,075 Steven Lefkowitz 16,007,358 1,132,543 21,612,075 Joseph Todisco 12,774,071 4,365,830 21,612,075 Robert Stewart 16,175,492 964,409 21,612,075”
Paulo F. Costa departed as Member of the Board of Directors at CorMedix Inc..
“On August 14, 2023, Paulo F. Costa, a member of the Board of Directors (the “Board”) of CorMedix Inc. (the “Company”), notified the Board that he will be retiring from the Board, effective as of October 15, 2023.”
Earnings Releases
CorMedix Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 8, 2023, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.”
Earnings Releases
CorMedix Inc. reported first quarter ended March 31, 2023 results: net income net loss of $10.6 million, EPS $0.24 per share.
“For the first quarter of 2023, CorMedix recorded a net loss of $10.6 million, or $0.24 per share, compared with a net loss of $7.0 million, or $0.18 per share, in the first quarter of 2022”
Robert Stewart was appointed as Director at CorMedix Inc..
“On April 13, 2023, the Board of Directors (the “Board”) of CorMedix Inc. (the “Company”) appointed Robert Stewart as a director, effective immediately”
Earnings Releases
CorMedix Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt, EPS $0.20 per share.
“CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022”
Earnings Releases
CorMedix Inc. reported the nine months ended September 30, 2022 results: net income $21.5 million, EPS $0.54 per share.
“For the nine months ended September 30, 2022, CorMedix recorded a net loss of $21.5 million, or $0.54 per share, compared with a net loss of $20.4 million, or $0.54 per share, in the first nine months of 2021.”
Earnings Releases
CorMedix Inc. reported the third quarter of 2022 results: net income $6.9 million, EPS $0.17 per share.
“For the third quarter of 2022, CorMedix recorded a net loss of $6.9 million, or $0.17 per share, compared with a net loss of $8.6 million, or $0.22 per share, in the third quarter of 2021.”
Matthew T. David changed role as Chief Financial Officer at CorMedix Inc..
“Dr. Matthew T. David will continue to serve as Interim Chief Executive Officer and Chief Financial Officer until Mr. Todisco commences employment, after which Dr. David will continue to serve as our Chief Financial Officer.”
Joseph Todisco was appointed as Director at CorMedix Inc..
“Mr. Todisco was appointed to serve as a member of the Board on March 18, 2022.”
Joseph Todisco was appointed as Chief Executive Officer at CorMedix Inc..
“appointed Joseph Todisco as the Chief Executive Officer, commencing on such date as mutually agreed by Mr. Todisco and the Board, but in no event later than May 16, 2022.”
Matt David was appointed as interim Chief Executive Officer at CorMedix Inc..
“On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.”
Matthew David was appointed as Interim Chief Executive Officer at CorMedix Inc..
“Matthew David, M.D., the Company’s current Chief Financial Officer, will serve as interim Chief Executive Officer, effective immediately, until a new Chief Executive Officer is appointed.”
John L. Armstrong, Jr. retired as Executive Vice President, Technical Operations at CorMedix Inc..
“On October 4, 2021, the Company and John L. Armstrong, Jr. came to a mutual agreement pursuant to which Mr. Armstrong will retire from his position as the Company’s Executive Vice President, Technical Operations, effective October 4, 2021.”
Khoso Baluch retired as Chief Executive Officer at CorMedix Inc..
“On October 1, 2021, the Company and Khoso Baluch came to a mutual agreement pursuant to which Mr. Baluch will retire from his position as the Company’s Chief Executive Officer, effective October 4, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.